ArticleAging2018
Spindle pole body component 25 regulates stemness of prostate cancer cells.
Article in Aging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- SPC25 promotes gastric cancer cells G1/S cell cycle transition and tumorigenesis by enhancing SLC1A5-mediated glutamine metabolism.Journal of bioenergetics and biomembranes · 2026Article
- Identification and validation of hub genes for kidney renal clear cell carcinoma treated with metformin and everolimus combination therapy.Translational cancer research · 2025Article
- SPC25 as a prognostic and immune-related biomarker in lung adenocarcinoma.Scientific reports · 2025Article
- Mefloquine Suppresses Metastasis in Renal Cell Carcinoma Through Targeting SPC25.Cancer science · 2025Article
- The multifaceted functions of SPC25 in cancer: from molecular pathways to targeted therapy.Frontiers in medicine · 2025Review
- Targeting the SPC25/RIOK1/MYH9 Axis to Overcome Tumor Stemness and Platinum Resistance in Epithelial Ovarian Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Spindle component 25 predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis.Scientific reports · 2024Article
- Article
- Identifying hub genes and common biological pathways between COVID-19 and benign prostatic hyperplasia by machine learning algorithms.Frontiers in immunology · 2023Article
- The synergistic effect ofAnnals of translational medicine · 2022Article
- SPC25 promotes hepatocellular carcinoma metastasis via activating the FAK/PI3K/AKT signaling pathway through ITGB4.Oncology reports · 2022Article
- Spindle pole body component 25 in the androgen-induced regression of castration-resistant prostate cancer.Translational andrology and urology · 2022Article
- Identification of Co-Expression Modules and Genes Associated With Tumor Progression in Oral Squamous Cell Carcinoma.Pathology oncology research : POR · 2022Article
- SPC25 promotes proliferation and stemness of hepatocellular carcinoma cells via the DNA-PK/AKT/Notch1 signaling pathway.International journal of biological sciences · 2022Article
- Role of spindle pole body component 25 in neurodegeneration.Annals of translational medicine · 2021Article
- Identification of hub genes in key hallmarks of ovarian cancer via bioinformatics analysis.Translational cancer research · 2021Article
- Article
- Article
- SPC25 may promote proliferation and metastasis of hepatocellular carcinoma via p53.FEBS open bio · 2020Article
- A prognostic 11-DNA methylation signature for lung squamous cell carcinoma.Journal of thoracic disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spindle pole body component 25 (SPC25) is a component of NDC80 complex that controls spindle assembly checkpoint in the microtubule-binding domain of kinetochores. We recently showed that SPC25 is required for prostate cancer (PrC) cell proliferation and cell cycle progression, and here we investigated whether SPC25 may be a Cancer stem cell (CSC) marker in PrC. We found that the levels of SPC25 were higher in PrC samples than paired normal prostate tissue. The overall survival of PrC patients with high SPC25 was poorer than those with low SPC25. PrC cell lines were transduced with two vectors carrying a luciferase reporter and a mCherry fluorescent reporter under a cytomegalovirus promoter and a nuclear green fluorescent protein reporter under the control of a SPC25 promoter, respectively, to allow differentiating SPC25+ from SPC25- PrC cells by flow cytometry. Compared to SPC25- cells, SPC25+ cells formed significantly more tumor spheres in culture, appeared to be more resistant towards docetaxel-induced cell apoptosis, and generated larger tumors with higher frequency after serial adoptive transplantation. Thus, our data suggest that SPC25 may be highly expressed in the CSC-like cells in PrC and could be a promising target for effective treatment of PrC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.